WCN26-6692 The sGC activator runcaciguat improves survival and renal function in hypertensive rats with chronic kidney disease

Read full text Summarise with VIRAT
Authors: Olga Gawryś, Šárka Vacková, Petra Škaroupková, Zuzana Honetschlägerová, Soňa Kikerlová, Zdeňka Vaňourková, Peter Sandner, Luděk Červenka
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) and related oxidative stress can dysregulate the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway, leading to reduced cGMP production. Insufficient cGMP levels are detrimental to the cardiovascular system and kidneys, accelerating renal damage and CKD progression. Runcaciguat, a novel sGC activator, shows strong potential as an effective treatment for CKD associated with hypertension, diabetes, or obesity. It selectively binds to oxidized and/or heme-free sGC under oxidative stress, enhancing cGMP production and exhibiting favorable pharmacokinetics with once-daily dosing.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Blood Pressure and Hypertension Studies Nitric Oxide and Endothelin Effects

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104510–104510
Publication date
25 March 2026
Language
EN